Biological markers may add to prediction of outcome achieved by the international prognostic score in Hodgkin's disease

Annals of Oncology

Volumn 11, Issue 11, 2000, Pages 1405-1411

  Axdorph, U ^a   Sjoberg J ^a   Grimfors, G ^a   Landgren, O ^a   Porwit MacDonald, A ^a   Bjorkholm M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Hodgkin's disease; Interleukin 10; Prognosis; Prognostic score; sCD30

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD30 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; THYMIDINE KINASE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0033635585     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026551727795     Document Type: Article

References (39)

1. Fixed versus response adapted MOPP/ABVD chemotherapy in Hodgkin's disease
2. Late effects of chemotherapeutic agents
3. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood
4. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment
5. Radiotherapy in early stage Hodgkin's disease. Principles and results of recent clinical trials
6. The role of radiotherapy for early stage Hodgkin's disease: Limitations and perspectives
7. Long-term outcome of treatment for Ann Arbor stage I Hodgkin's disease: Prognostic factors for survival and freedom from progression
8. Treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease: The Swedish National Care Program experience
9. Prognostic factors in Hodgkin's disease. II. Role of the lymphocyte defect
10. Lymphocyte function in untreated Hodgkin's disease: An important predictor of prognosis
11. Lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease
12. Acute phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin's disease
13. Increased serum CD8 soluble antigen level is associated with blood lymphocyte abnormalities and other established indicators of poor prognosis in adult Hodgkin's disease
14. Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma
15. Serum levels of interleukin-2 receptor (CD25) in patients with Hodgkin's disease, with special reference to age and prognosis
16. Serum levels of soluble Interleukin-2 receptor (sCD25) are increased in untreated patients with Hodgkin's disease with impaired blood lymphocyte function and a poor prognosis
17. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: Outcome and clinical implications
18. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome
19. Soluble ICAM-1 in Hodgkin's disease: A promising independent predictive marker for survival
20. Serum levels of sICAM-1 are correlated to tumour burden and blood lymphocyte functions in untreated Hodgkin's disease
21. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival
22. Prognostic role of serum β2-microglobulin in Hodgkin's disease
23. Serum thymidine kinase as a prognostic marker in Hodgkin's disease
24. Serum interleukin-6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms
25. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients
26. A prognostic score for advanced Hodgkin's disease
27. Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients?
28. Prognostic factors of Hodgkin's disease
29. A practical approach to the pathology of lymphoid neoplasms: A revised European-American classification from the international lymphoma study group
30. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease
31. Report of the committee on Hodgkin's disease staging classification
32. Prognostic factors in Hodgkin's disease. I. Analysis of histopathology, stage distribution and results of therapy
33. Prognostic influence of early diagnostic splenectomy in Hodgkin's disease. A long-term follow-up
34. Nonparametric estimation from incomplete observations
35. A generalised Wilcoxon test for comparing arbitrarily single-censored samples
36. Regression models and life tables
37. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels
38. Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin's disease, the Milan Cancer Institute Experience
39. Prognostic score for Hodgkin's disease